BackIdera Pharmaceuticals Overview

Idera Pharmaceuticals Receivables

Track Idera Pharmaceuticals's receivables ($2.2M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Receivables
$2.20M

Peer average

Loading

Idera Pharmaceuticals Receivables History

Loading

Idera Pharmaceuticals vs. peers: Receivables Comparison

Loading

Idera Pharmaceuticals Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Idera Pharmaceuticals (IDRA) FAQ

Idera Pharmaceuticals (IDRA) currently reports a receivables of $2.2M as of March 2023. In the prior-year period, the figure was $0. Use the charts on this page to explore Idera Pharmaceuticals's receivables history and peer comparisons.

Idera Pharmaceuticals's receivables changed from $0 to $2.2M (period ending March 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Idera Pharmaceuticals reported $2.2M in receivables as of March 2023. In the prior-year period, the figure was $0. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $2.2M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Idera Pharmaceuticals, and consider following IDRA for alerts when major investors trade the stock.

Idera Pharmaceuticals is classified in the Healthcare sector. On receivables, it currently shows $2.2M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing IDRA with unrelated industries.